Latest Innovation News

Wagners Holding Company Limited has launched a A$30 million institutional placement to reduce debt and accelerate growth in its core Construction Materials and Composite Fibre Technologies businesses following a robust FY25 performance.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

Rewardle Holdings reported a modest revenue increase for FY25 but saw its loss more than double, driven by investments in AI-powered MedTech associate CloudHolter and expanded platform initiatives.

Metal Powder Works Limited has completed a A$15 million institutional placement, strengthening its balance sheet to scale production and expand its market presence.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

Hazer Group and First Graphene have signed a non-binding MOU to explore innovative applications for Hazer’s proprietary graphite, aiming to capitalize on rising global demand amid supply constraints.

Janus Electric has launched a strategic pilot project in Southern California, delivering battery-swapping Class 8 trucks and solar-powered infrastructure to revolutionize zero-emission freight at major U.S. ports.

Prophecy International flags higher churn and softer US sales for its Snare product, prompting a conservative FY2026 outlook and $3.2 million in annual cost savings.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

S&P Dow Jones Indices has announced its September 2025 quarterly rebalance, reshuffling key constituents across multiple S&P/ASX indices effective September 22. The changes highlight shifting market dynamics with notable additions and removals in sectors ranging from technology to resources.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Lake Resources N.L. has scheduled an Extraordinary General Meeting on 7 October 2025 to seek shareholder approval for the second tranche of its $12 million placement and the issuance of new options to investors and directors.